CGP-37849

CGP-37849

Clinical data
Other names	CGP-37849, CGP-40116
Identifiers
IUPAC name (E,2R)-2-amino-4-methyl-5-phosphonopent-3-enoic acid
CAS Number	137424-81-8  Y
PubChem CID	6604869
ChemSpider	5037128  N
UNII	76IND1BS43
ChEMBL	ChEMBL29811  N
CompTox Dashboard (EPA)	DTXSID901214124
Chemical and physical data
Formula	C6H12NO5P
Molar mass	209.138 g·mol−1
3D model (JSmol)	Interactive image
SMILES C/C(=C\[C@H](C(=O)O)N)/CP(=O)(O)O
InChI InChI=1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+/t5-/m1/s1 N Key:BDYHNCZIGYIOGJ-XWCPEMDWSA-N N
NY  (what is this?)    (verify)

CGP-37849 is a competitive antagonist at the NMDA receptor. ^[1] It is a potent, orally active anticonvulsant in animal models, ^[2] and was researched for the treatment of epilepsy. ^[3] It also has neuroprotective activity ^[4] and shows antidepressant ^{[5] [6]} and anxiolytic effects. ^{[7] [8]}

References

1. Fagg GE, Olpe HR, Pozza MF, Baud J, Steinmann M, Schmutz M, et al. (April 1990). "CGP 37849 and CGP 39551: novel and potent competitive N-methyl-D-aspartate receptor antagonists with oral activity". British Journal of Pharmacology. 99 (4): 791–7. doi:10.1111/j.1476-5381.1990.tb13008.x. PMC   1917531 . PMID   1972895.
2. Schmutz M, Portet C, Jeker A, Klebs K, Vassout A, Allgeier H, et al. (July 1990). "The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent, orally-active anticonvulsants in rodents". Naunyn-Schmiedeberg's Archives of Pharmacology. 342 (1): 61–6. doi:10.1007/bf00178973. PMID   1976233. S2CID   25531153.
3. Fujikawa DG, Daniels AH, Kim JS (March 1994). "The competitive NMDA receptor antagonist CGP 40116 protects against status epilepticus-induced neuronal damage". Epilepsy Research. 17 (3): 207–19. doi:10.1016/0920-1211(94)90051-5. PMID   7912191. S2CID   13656613.
4. Gutnikov SA, Gaffan D (June 1996). "Systemic NMDA receptor antagonist CGP-40116 does not impair memory acquisition but protects against NMDA neurotoxicity in rhesus monkeys". The Journal of Neuroscience. 16 (12): 4041–5. doi:10.1523/JNEUROSCI.16-12-04041.1996. PMC   6578604 . PMID   8656297.
5. Maj J, Klimek V, Gołembiowska K, Rogóz Z, Skuza G (1993). "Central effects of repeated treatment with CGP 37849, a competitive NMDA receptor antagonist with potential antidepressant activity". Polish Journal of Pharmacology. 45 (5–6): 455–66. PMID   7912134.
6. Papp M, Moryl E (September 1994). "Antidepressant activity of non-competitive and competitive NMDA receptor antagonists in a chronic mild stress model of depression". European Journal of Pharmacology. 263 (1–2): 1–7. doi:10.1016/0014-2999(94)90516-9. PMID   7821340.
7. Jessa M, Nazar M, Bidzinski A, Plaznik A (March 1996). "The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety". European Neuropsychopharmacology. 6 (1): 55–61. doi:10.1016/0924-977x(95)00068-z. PMID   8866939. S2CID   45953054.
8. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E (July 2000). "The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats". Neuropharmacology. 39 (10): 1858–64. doi:10.1016/s0028-3908(00)00023-x. PMID   10884566. S2CID   33660694.